Tropifexor, another highly potent non-bile acid FXR agonist, is being tested in a phase 2 clinical trial (FLIGHT FXR, NCT02855164) in patients with stage 1–3 fibrosis due to NASH. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.